Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Geovax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus (HIV), as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeoVax Labs advances cancer therapies and COVID-19 vaccine development

GeoVax Labs showcased advancements in cancer therapies and COVID-19 vaccine development, underlining a commitment to innovation and global healthcare improvement.
While facing financial challenges due to increased R&D expenses and net loss, GeoVax's strategic strengths in vaccine development and clinical trials offer promising opportunities for growth.
The completion of the Gedeptin trial, ongoing Phase II trials for CM04S1, and plans for future vaccine developments position GeoVax for impactful contributions to healthcare.

GeoVax Labs reports Q2 loss, progresses in key trials

GeoVax's Q2 performance reflects ongoing investment in R&D and progress in key clinical trials.
The company's strengths lie in securing funding, commitment to innovation, and vaccine differentiation.
Challenges include recruitment issues, funding needs, and uncertainties in the pipeline.
Opportunities exist in fundraising, vaccine development, expanding indications, and optimizing clinical trials.

GeoVax Labs reports Q3 progress with vaccine trials and financial challenges

GeoVax Labs' Q3 performance reflects a mix of achievements and challenges, with a focus on advancing vaccine candidates and managing financials. The company's strengths in innovation and clinical trial strategies position it well for future growth opportunities through partnerships and regulatory advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

GeoVax Labs Inc (NASDAQ: GOVX) entered into an exclusive license agreement with City of Hope, a cancer research and treatment organization, for COH04S1, a synthetic, attenuated modified vaccinia Ankara vector expressing spike and nucleocapsid antigens of the SARS-CoV-2 virus.  GeoVax has exclusive rights to develop and commercialize a multi-antigenic SARS-CoV-2 vaccine candidate developed at the City of Hope for immunocompromised patients.

GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate

Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients

GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope's COVID-19 Vaccine

Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time

GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update

Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 3% during intraday trading today. This is why it happened.

GOVX Stock: Why It Increased Today

GeoVax Labs Inc (NASDAQ: GOVX) entered into a license agreement with PNP Therapeutics Inc to develop and commercialize Gedeptin for solid tumors.   The transaction's detailed financial terms were not disclosed but include a combination of upfront payments, milestone fees, and royalties on net sales.

GeoVax Stock Is Trading Higher On Gedeptin In-Licensing Pact For Solid Tumors

License of Gedeptin® Adds Orphan Drug Clinical Program for  Treatment of Advanced Head and Neck Cancers

GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program

Atlanta, GA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  GeoVax Labs, Inc . (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announces today that Chairman & CEO David Dodd will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13-15, 2021.

GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

The shares of Geovax Labs Inc (NASDAQ: GOVX) increased 32.79% in the previous trading session. This is why it happened.

Geovax Labs Shares Increased 32.79%: Why It Happened

Geovax Labs (GOVX) stock is soaring higher on Friday after the company presented COVID-19 vaccine data at a recent conference. The post GOVX Stock: Why GeoVax Shares Are Skyrocketing Today appeared first on InvestorPlace.

GOVX Stock: Why GeoVax Shares Are Skyrocketing Today

Geovax Labs Inc (NASDAQ: GOVX) is trading significantly higher Friday after the company announced it presented data from ongoing studies of its preventive vaccine against COVID-19 at the European Society of Medicine General Assembly. Using its novel Modified Virus Ankara-Virus Like Particle (GV-MVA-VLP) platform, GeoVax has developed a design strategy for vaccines expected to induce broader immunity through inclusion of multiple structural and nonstructural proteins from the target pathogen.

Why Geovax Labs Shares Are Soaring Today

The shares of GeoVax Labs, Inc. (Nasdaq: GOVX) increased by over 70% pre-market. This is why it happened.

GeoVax Shares Increase Over 70% Pre-Market: Why It Happened

ATLANTA, GA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- GeoVax Vaccine Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants

GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly

ATLANTA, GA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Wednesday, August 18, 2021 at 12:30 PM EST. David Dodd, Chairman and CEO, will be hosting the presentation and answering questions from investors.

GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q2 2021 Results - Earnings Call Transcript

Continued Progress on COVID-19 and Immuno-Oncology Programs

GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update

Conference call to be held Wednesday, August 11, at 4:30 p.m. Eastern Time

GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update

The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 10% during intraday trading. This is why it happened.

GOVX Stock Increases Over 10% Intraday: Why It Happened

GeoVax Vaccine Achieves 100% Protection in a Single-Dose

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

Vaccine Would Address Therapeutic Medical Need of Over 250 Million Worldwide

GeoVax Announces Issuance of Hepatitis B Vaccine Patent

Atlanta, GA, June 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --  GeoVax Labs, Inc . (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that it will be participating in the Alliance Global Partners' Virtual Healthcare Symposium being held on Thursday, June 17, 2021.

GeoVax to Participate in the Alliance Global Partners' Virtual Healthcare Symposium

GeoVax Chairman & CEO to Participate in Vaccine Panel Discussion

GeoVax to Present at 2021 BIO Digital

Atlanta, Georgia--(Newsfile Corp. - May 11, 2021) - GeoVax Labs, Inc. (NASDAQ: GOVX) today announced that David Dodd, Chairman & CEO will be attending the Q2 Virtual Investor Summit.  Event Q2 Investor Summit Date May 17-18th, 2021 Presentation May 18th at 8:45 AM ET

GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q1 2021 Results - Earnings Call Transcript

Additional Capital Raised to Support Acceleration of Coronavirus and Immuno-Oncology Programs

News for Geovax Labs Stock (GOVX)